For how we live.
ECDC data show near-zero hepatitis B in under-fives and vertical transmission below 2%, alongside five million chronic infections and only seven countries meeting the harm-reduction benchmark.
Hepcludex clears a bar most rare-disease drugs never reach: full U.S. approval. But FDA granted it on a surrogate marker, denied a bonus review voucher, and wants outcomes data that won't arrive until 2034.
Judge Brian Murphy found the government likely broke two federal laws when it bypassed ACIP and replaced its members. The ruling reverts the childhood schedule and cancels this week's ACIP meeting.
The objection turns on a no-treatment arm. WHO says placebo or no-treatment vaccine trials are acceptable only where no proven intervention exists, and here one does.
The American Academy of Pediatrics' 2026 schedule covers 18 diseases and carries 12 outside endorsements. The federal schedule signed three weeks earlier lists 11 vaccines for all children.
Eleven vaccines remain recommended for all children. The rest move to risk-based or shared-decision categories, on the strength of a comparison with 20 other countries.
A federal recommendation is load-bearing for insurance coverage, the Vaccines for Children programme, and school requirements. States have started building alternatives to all three.
The 5 December directive tells HHS and the CDC to compare the American childhood schedule with those of other wealthy nations, using a count of diseases as its benchmark.
ACIP replaced a recommendation in place since 1991 with individual decision-making for babies born to mothers who test negative. The CDC has not yet adopted it.
The committee meets 18-19 September on COVID-19, hepatitis B and MMRV vaccines. RSV was dropped two days before. Adopted recommendations carry insurance and Vaccines for Children consequences.